SHANGHAI, China, January 1, 2019 – Asieris Pharmaceuticals, a clinical-stage biopharmaceutical company, announced today that Dr. Kevin Pan, the company CEO, will participate in and serve as a panelist on the “China-Europe Partnering & Investment Panel” at the 12th Annual European Life Sciences CEO Forum (ELSCEO) Forum in Zurich, Switzerland, February 25-26th, 2019. This global bio-pharma industry forum addresses the main challenges for 2019 in investment, partnering and alliance management. Key leaders contribute their insights through multiple panels covering such topics as the industry landscape and innovation in different therapeutic sectors.
About Asieris Pharmaceuticals
Asieris Pharmaceuticals is dedicated to becoming a specialty pharmaceutical company focusing on discovery, development and commercialization of innovative therapies to treat genito-urinary diseases. Founded in 2010, Asieris currently has operations in Shanghai, Beijing, Taizhou City of Jiangsu Province, and the United States. Asieris’ strategy is to build a strong pipeline through internal R&D and in-licensing, develop and commercialize products in China and gain access to ex-China markets with global partners.
